mk-0616
merck
[]
more ldl-c therapies in the pipeline. oral pcsk9 phase 2b study shows up to 61% ldl-c reduction. well tolerated. diverse population enrolled across ascvd risk categories. more to come! #acc2023 
She/her. Cardiologist & Health Equity Researcher @StanfordMed #prevention, mom of 3. Views are my own.